Suboptimal Responses in Chronic Myeloid Leukemia
The high response rates and increased survival associated with imatinib therapy prompted a paradigm shift in the management of chronic myeloid leukemia. However, 25% to 30% of imatinib-treated patients develop drug resistance or intolerance, increasing the risk of disease progression and poor progno...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Wiley Subscription Services, Inc., A Wiley Company
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412948/ |